Table 1 Baseline characteristics
|  | Ovarian cancer (n = 30) | Triple-negative breast cancer (n = 22) |
|---|---|---|
Age, years | 54.5 (44–70) | 53 (22–66) |
ECOG performance status | ||
 0 | 19 (63.3%) | 18 (81.8%) |
 1 | 11 (36.7%) | 4 (18.2%) |
Histology type | ||
 High-grade serous | 30 (100%) | - |
No. of lines of previous palliative chemotherapy | ||
 2 | 21 (70.0%) | 22 (100%) |
 3 | 7 (23.3%) | 0 |
 4 | 2 (6.7%) | 0 |
Invasive metastasis | ||
 Yes | 12 (40.0%) | 13 (59.1%) |
 No | 18 (60.0%) | 9 (40.9%) |
No. of metastasis sites | ||
 1 | 4 (13.3%) | 7 (31.8%) |
 2 | 14 (46.7%) | 12 (54.6%) |
 3 | 6 (20.0%) | 3 (13.6%) |
  ≥ 4 | 6 (20.0%) | 0 |
CA-125 | ||
  < ULN | 4 (13.3%) | - |
  ≥ ULN- < 2ULN | 3 (10.0%) | - |
  ≥ 2ULN | 22 (73.3%) | - |
BRCA mutation status | ||
 Mutation carrier | 8 (26.7%) | 3 (13.6%) |
 Wild-type | 22 (73.3%) | 19 (86.4%) |
Platinum status | ||
 Sensitive | 10 (33.3%) | - |
 Resistant | 17 (56.7%) | - |
 Refractory | 3 (10.0%) | - |